New trial aims to improve survival for a tough pancreatic cancer
NCT ID NCT07155629
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial will test whether giving chemotherapy before surgery helps people with resectable left-sided pancreatic cancer live longer compared to surgery alone. About 381 participants will be randomly assigned to either neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) followed by surgery, or upfront surgery. The study aims to fill a gap in evidence for this specific tumor location.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mFOLFIRINOX or nab-paclitaxel plus gemcitabine chemotherapy
What this could lead to
If it works, this could show that giving chemotherapy before surgery helps people with left-sided pancreatic cancer live longer.
What could go wrong
This is a phase 3 trial, but results are not yet available. Chemotherapy has side effects, and it may not improve survival compared to surgery alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helsinki University Central Hospital
Helsinki, 00290, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oulu University Hospital
Oulu, 90220, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••